Sotatercept (mIgG2a)

Synonyms: RAP-011
Sotatercept (mIgG2a) (RAP-011) 是 Sotatercept (ACE-011) (MS-I13382) 的小鼠同源物,作为一种可溶性激活素受体 IIA (ActRIIA) 配体陷阱,它通过结合并中和激活素 A 及其他 TGF-β 超家族成员(如 Activin A/B、GDF11 和 BMP9/10)来抑制这些配体与其受体的结合,从而调节细胞增殖和分化,主要抑制 SMAD2/3 信号通路,可用于慢性肾病等多种疾病,并能降低促红细胞铁调素 (ERFE) 表达、调节铁代谢、促进红细胞生成,同时具有促进骨形成(促合成代谢)和抑制骨吸收(抗分解代谢)的双重作用。
Sotatercept (mIgG2a)
产品编号: MS-G67561 纯度: 99.93% 分子量: 79.67 kDa
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
1mg
询价
3-5 天
5mg
询价
询价
10mg
询价
询价
50mg
询价
询价

产品描述

Sotatercept (mIgG2a) (RAP-011) 是 Sotatercept (ACE-011) (MS-I13382) 的小鼠同源物,作为一种可溶性激活素受体 IIA (ActRIIA) 配体陷阱,它通过结合并中和激活素 A 及其他 TGF-β 超家族成员(如 Activin A/B、GDF11 和 BMP9/10)来抑制这些配体与其受体的结合,从而调节细胞增殖和分化,主要抑制 SMAD2/3 信号通路,可用于慢性肾病等多种疾病,并能降低促红细胞铁调素 (ERFE) 表达、调节铁代谢、促进红细胞生成,同时具有促进骨形成(促合成代谢)和抑制骨吸收(抗分解代谢)的双重作用。

生物实验数据

生物活性 Sotatercept (mIgG2a) (RAP-011), the mouse homolog of Sotatercept (ACE-011) (MS-I13382), is a soluble activin receptor type IIA (ActRIIA) ligand trap that binds to and neutralizes activin A and other TGF-β superfamily members (such as Activin A/B, GDF11, and BMP9/10), thereby inhibiting the binding of these ligands to their receptors and modulating cell proliferation and differentiation; it primarily inhibits the SMAD2/3 signaling pathway and can be used in various diseases including chronic kidney disease, reduces erythroferrone (ERFE) expression, regulates iron metabolism, promotes erythropoiesis, and exerts a dual effect of promoting bone formation (anabolic) and inhibiting bone resorption (anti-catabolic).
体外研究
(In Vitro)

Sotatercept (mIgG2a) (0.05 g/L, 1 h-5 d) 能够抑制 SMAD2 的磷酸化以及 ERFE 的表达,促使转录因子 GATA1 进入细胞核,并恢复红细胞标志物的基因表达。

RT-PCR

Cell Line: K562 cells
Concentration: 0.05 g/L with 50 ng/mL GDF11
Incubation Time: 5 d
Result: Significantly upregulated the erythroid differentiation markers (such as KLF1, ABCB6, etc.).
Upregulated the anti-apoptotic gene BCL2 and downregulated the pro-apoptotic genes BAX/BAD.
Significantly reduced the expression of mRNA ERFE.

Western Blot Analysis

Cell Line: K562 cells
Concentration: 0.05 g/L with 50 ng/mL GDF11
Incubation Time: 0.5, 1, 2 h
Result: Significantly inhibited the phosphorylation of SMAD2 induced by GDF1.
Promoted the nuclear translocation of GATA1, accompanied by an increase in nuclear expression of HSP70 and a decrease in nuclear expression of SMAD4.
Significantly reduced the expression of ERFE protein.
体内研究
(In Vivo)

Sotatercept (mIgG2a) (0.1-10 mg/kg,皮下注射,每周两次,持续 2-6 周) 可有效促进大鼠修复过程中的骨形成。
Sotatercept (mIgG2a) (30 mg/kg,腹腔注射,每日一次,持续 10 天) 在促进 Hamp 转基因小鼠的红细胞生成方面表现出显著效果,同时避免了促红细胞生成素 (HY-P70409) 治疗中常见的铁缺乏问题。
Sotatercept (mIgG2a) (10 mg/kg,皮下注射,每周两次,持续 6 周) 可预防慢性肾脏病 (CKD) 小鼠模型中的血管钙化和肾脏纤维化。

Animal Model: Closed femoral fracture surgery established in 8-week male Wistar rats
Dosage: 0.6 mg/kg biw (x 2 doses) + 0.35 mg/kg biw (x 3 doses); 0.18 mg/kg biw (x2 doses) + 0.1 mg/kg biw (x 7 doses) and 10mg/kg biw (x 12 doses)
Administration: Subcutaneous injection (s.c.), twice a week for 2-6 weeks
Result: Significantly increased callus length and bone volume at high-dose RAP-011 (10mg/kg biw), but the quality of the newly formed bone tissue was relatively low, and the improvement in mechanical properties was limited.
Demonstrated certain anabolic effects at low-dose pulsed administration.
No obvious effect at continuous low-dose administration.
Animal Model: Iron-deficiency anemia model established in C57BL/6 mice and in hepcidin antimicrobial peptide over expressing mice (Tg-Hamp mice)
Dosage: 30 mg/kg
Administration: Intraperitoneal injection (i.p.), once daily for 10 days
Result: Significantly increase the hemoglobin concentration in both wild-type and Tg-Hamp mice (better).
Promoted the production of red blood cells while not causing excessive depletion of iron reserves.
Significantly increased the proportion of late erythroid precursor cells (the CD44low population).
Did not change the expression level of Hamp.
Animal Model: CKD that stimulated atherosclerotic calcification model established in high fat fed ldlr−/− mice
Dosage: 10 mg/kg
Administration: Subcutaneous injection (s.c.), twice weekly for 6 weeks
Result: Reduced the calcium content and calcium deposits in the aortal.
Increased the markers of vascular smooth muscle (sm22α, αSMA) and reduced osteogenic markers (Runx2, alkaline phosphatase).
Restored the ActRIIA signal and regulated the Wnt signal.
Inhibited fibrosis mediated by Smad, increased the expression of klotho and downregulated the Wnt/Dkk1 signaling pathway.
性状 液体
颜色 Colorless to light yellow

化学信息

分子量 79.67 kDa
别名 RAP-011

储存&溶解度

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.

运输条件 Shipping with dry ice.

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础